Recherche
Résultats 1-7 de 7
-
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Journal of clinical oncology, 2017, 35, 2473Article dans une revue scientifique -
Eight Cycles of ABVD Versus Four Cycles of BEACOPP(escalated) Plus Four Cycles of BEACOPP(baseline) in Stage III to IV, International Prognostic Score >= 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial
Journal of clinical oncology, 2016, 34, 2028-+Article dans une revue scientifique -
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials
Journal of clinical oncology, 2017, 35, 552Article dans une revue scientifique -
Through the Glass Ceiling.
Journal of clinical oncology, 2018, JCO2017763961Article dans une revue scientifique -
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy
Journal of clinical oncology, 2017, 35, 1905-+Article dans une revue scientifique -
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
Journal of clinical oncology, 2017, 35, 3898-+Article dans une revue scientifique -
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma
Journal of clinical oncology, 09-2015, 33, 2803-U127Article dans une revue scientifique